Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir;Tratamiento profiláctico y anticipado de la infección por citomegalovirus en pacientes trasplantados renales mediante vanglanciclovir oral

Nefrologia

Volumn 28, Issue 3, 2008, Pages 293-300

  Guirado, Luis ^a   Rabella, N ^b   Diaz J M ^a   Facundo, C ^a   Maderuelo, A ^a   Margall, N ^b   Silva, I ^a   Garcia Maset R ^a   Calabia, J ^a   Gimenez I ^a   Garra, N ^a   Sola R ^a   Ballarin J A ^a  

^a FUNDACIÓ PUIGVERT   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Cytomegalovirus; Oral vanganciclovir; Quantitative PCR; Renal transplant

Indexed keywords

ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR; VALGANCICLOVIR;

ADOLESCENT; ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; ORAL DRUG ADMINISTRATION; RISK FACTOR;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; RISK FACTORS;

EID: 51349117808     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fishman J, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998: 338: 1741.
2. Rubin RH. Clinical approach to infection in the compromised host. En: Rubin RH, Young LS, eds. Infection in the Organ Transplant Recipient. New York, NY: Kluwer Academic Press, 2002: 573.
3. Vanèiková Z, Dvorâk P. Cytomegalovirus infection in immunocompromised individuals - a review. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1: 179-187.
4. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid organ transplant recipients.
5. Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999; 1: 8-12.
6. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261: 3607-3609.
7. Sageda S, Nordal KP, Hartmann A, Sund S, Scott H, Degré M y cols. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-856.
8. Lemström K, Koskinen P, Krogerus L, Daemen M, Bruggeman C, Häyry P. Cytomegalovirus antigen expression, endothelial cell proliferation and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Circulation 1995; 92: 2594-2604.
9. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 70-78.
10. Das A. Cytomegalovirus infection in solid organ transplantation: economic implications. Pharmacoeconomics 2003; 21: 467-475.
11. Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteraemia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1996; 23: 468-474.
12. Hodson EM, Jones ChA, Webster AC, Strippoli GM, Barclay PG, Kable K, Vimalachandra D, Craig JC. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 2105-15.
13. Paya C, Humar A, Domínguez E y cols. Efficacy and safety or valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
14. Balfour HH Jr, Chase BA, Spatulation JT, Simmons LR, Fry DS. A randomized, placebo-controlled trial of oral aciclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320:1381-7.
15. Vila A, Guirado LL, Balius A, Díaz M, Baro E, Olaya M, Andrade M, Agraz I, Sola R. Aciclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients. Transplant Proc 1999 Sep; 31 (6): 2335-6
16. Guirado L, Herreros MA, Muñoz JM, Rabella N, Facundo C, Agraz I, Díaz M, Díaz JM, Durán F, Sola R. Use of cytomegalovirus antigenemia as a marker for preemptive treatment. Transplant Proc 2002 Feb; 34 (1): 67-8.
17. Chou S. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 2001; 3: 20.
18. Pescovitz MD, Rabkin J, Merion RM y cols. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811
19. Boivin G, Goyette N, Gilbert E, Covington E. Analysis of Cytolegalovirus DNA Polymerase (UL54) Mutations in Solid Organ Transplant Patients Receiving Valganciclovir Ganciclovir Prophylaxis. J Med Virol 2005; 77: 425-429.
20. Kalil AC, Levitsky J, Lyden E, Stoner J, Frelfeld AG. Meta-Analysis: The Efficacy of Strategies to Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients. Ann Intern Med 2005; 143: 870-880.